In the landscape of modern drug discovery, a quiet but profound transformation is underway. What was once a linear, paper-and-glass-bound process—where tissue samples were analyzed, recorded, and promptly archived in cold storage—is evolving into a dynamic, data-driven ecosystem. Driven by the maturation of digital pathology and a rigorous push from regulatory bodies to reduce reliance on animal models, researchers are finding that the key to future innovation lies in the archives of the past.
By leveraging digitized slides, artificial intelligence, and molecular re-analysis of legacy tissue, the scientific community is beginning to "mine" existing data to answer complex biological questions without the need for additional animal testing. This paradigm shift, spearheaded by institutions like Charles River Laboratories, marks a departure from traditional "one-way street" pathology toward a model of perpetual utility.
The Evolution of the Digital Slide
For decades, the pathology workflow was defined by the physical limits of the microscope. A pathologist would examine a glass slide, dictate findings, and that slide would essentially reach the end of its functional life. The COVID-19 pandemic served as an unexpected catalyst for change; as travel and lab access became restricted, digital pathology transitioned from a niche academic interest to an operational necessity.
"Before, the pathology endpoint was just a report," explains Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories. "Now you have the digitized slide, which is essentially pixels."
This transition to digital storage has unlocked the ability to treat histology slides as rich datasets. When paired with original pathology reports and molecular measurements, these digital files can be used to train machine learning models capable of identifying subtle, non-obvious patterns linked to molecular changes within tissue. A single slide, once viewed only for a specific toxicological endpoint, has now become an evergreen source of information.
Chronology of a Regulatory and Scientific Pivot
The journey toward a non-animal-centric research model has accelerated significantly over the last decade. The timeline of this shift reflects a confluence of technological capability and legislative pressure:
- Pre-2020: Digital pathology is primarily used for remote consultation and education, with limited integration into standard toxicological workflows.
- 2020–2022: The global pandemic mandates remote work, forcing the rapid adoption of digital slide scanning and cloud-based analysis, establishing the digital infrastructure necessary for large-scale data mining.
- 2022: The FDA Modernization Act 2.0 is enacted, legally permitting non-animal methods to support human clinical trial applications, signaling a formal shift in regulatory philosophy.
- April 2024: Charles River Laboratories launches its Alternative Methods Advancement Project (AMAP), a strategic initiative aimed at reducing, refining, and replacing animal testing.
- April 2025: The FDA releases its comprehensive roadmap for reducing animal testing, starting with monoclonal antibodies and outlining a transition strategy to make New Approach Methodologies (NAMs) the standard.
- September 2026: The FDA updates its regulations, providing concrete guidance for the adoption of innovative alternatives to animal testing, further solidifying the industry’s trajectory.
Extracting More from the Animals We Already Use
One of the most promising avenues for reducing animal usage lies in the implementation of "virtual control groups." In standard toxicology, a significant portion of study animals are used solely as concurrent controls to provide a baseline for comparison. By leveraging robust historical data, researchers can now create "virtual" control cohorts, mathematically matched to study conditions.
"Control animals are always a big fraction of every study," Dr. Zuraw notes. By replacing a subset of these controls with matched historical data, laboratories can significantly reduce the number of animals required for a given protocol. However, this is not merely a matter of data substitution; it requires a rigorous validation process to ensure that historical baseline conditions are statistically comparable to current study parameters, preventing potential misinterpretations of drug effects.
The Role of FFPE Archives
Toxicology studies rely heavily on Formalin-Fixed, Paraffin-Embedded (FFPE) blocks. These blocks, usually consigned to long-term storage, are now being viewed as gold mines for molecular investigation. While fresh-frozen tissue is often preferred for molecular analysis, it requires prospective planning. When a new research question arises after the conclusion of a study, the archive of FFPE blocks provides a way to retrospectively analyze gene expression and protein levels.
According to 2025 guidance from the Organisation for Economic Co-operation and Development (OECD), while sample preparation remains critical, the systematic analysis of stored FFPE tissue can provide valuable molecular insights, effectively extending the lifespan of the original research effort.
Supporting Data: The Rise of Virtual Staining
Perhaps the most "cutting-edge" development in this space is virtual staining. This technology allows researchers to scan unstained tissue sections and use software to generate the digital appearance of a stain. This bypasses the physical and chemical processes of traditional staining, potentially reducing the consumption of reagents and the logistical burden of physical slide preparation.
Evidence suggests this is not merely a theoretical exercise. A 2026 review indicates an accelerating proliferation of virtual histology across diverse tissue types. As laboratories invest in the high-resolution scanners and computational infrastructure required for digital pathology, they create a "snowball effect." With the infrastructure already in place for routine diagnosis, the barrier to entry for advanced AI-driven analysis drops, encouraging more researchers to explore these methodologies.
Official Responses and Regulatory Guidance
The shift toward NAMs is no longer just a trend; it is a regulatory expectation. The FDA’s commitment to transitioning away from animal models as the "default" for preclinical safety studies is clear. The agency’s roadmap, published in April 2025, establishes a three-to-five-year horizon for making animal studies the exception.
However, regulatory approval is contingent upon transparency and reproducibility. As Dr. Zuraw points out, the transition to routine practice requires a vanguard of "early adopters." These institutions are tasked with troubleshooting these new methodologies, establishing best practices, and generating the precedent necessary for broader industry adoption. By sharing these findings, early adopters provide a blueprint that others can follow, ensuring that the industry does not "reinvent the wheel" with every new project.
Implications for the Future of Drug Discovery
The implications of this shift are profound, impacting everything from cost-efficiency to ethical standards and the speed of drug development.
- Ethical Advancement: The most immediate impact is the significant reduction in the number of animals required for preclinical safety assessments. This aligns with the "3Rs" principle (Replacement, Reduction, and Refinement) that governs modern ethical research.
- Data Depth: By moving beyond the physical limitations of the glass slide, researchers can integrate multi-omics data with histopathology. This creates a holistic, systems-level view of how a drug candidate interacts with biological systems, potentially identifying toxicities earlier in the development lifecycle.
- Economic Efficiency: While the initial investment in digital infrastructure is substantial, the long-term potential for cost savings is significant. By utilizing virtual controls and mining existing archives, firms can optimize their R&D spend, avoiding the high costs of redundant animal studies.
- Scientific Integrity: Digital pathology allows for more objective, AI-assisted quantitation. Unlike human visual estimation, which can be subject to inter-observer variability, digital algorithms provide consistent, repeatable measurements, enhancing the rigor of toxicological assessments.
As we look toward the remainder of the decade, the integration of digital pathology into the mainstream of preclinical research seems inevitable. The ability to revisit the past—to re-examine, re-analyze, and re-interpret the vast archives of historical tissue—is providing the scientific community with a powerful new tool. By turning data that was previously "locked" in physical form into actionable digital insights, researchers are not only accelerating the pace of drug discovery but are also fundamentally redefining the relationship between technology, ethics, and biology.
The "snowball effect" described by Dr. Zuraw is already gaining momentum. As more labs transition to digital sign-outs and adopt advanced molecular prediction models, the industry moves closer to a future where the next breakthrough might not be found in a new test tube, but in a digital file created years ago.
About the Author
